DAPA - Egypt Study

Status Completed

Clinical Trial Summary

Approximately 39 million people of adults aged 20-79 are living with Diabetes in MENA region in 2017, Egypt is number 8 in the top 10 countries in number of adults with Diabetes (8.2 million), where Egypt represents 21% of the Diabetics in MENA region. Metformin is used as 1st line oral anti-diabetic drug in most cases. Sulfonylureas (SU) are used as frequent first add-on after failure of metformin monotherapy. Sodium Glucose Co-transporter 2 (SGLT2) inhibitors are a newer class of therapy which has a lower incidence of hypoglycemia and in addition helps in weight and BP reduction. In Egypt, SGLT2 inhibitors were introduced in 2016. It is not yet widely used for various reasons including lack of wide clinical experience in Egyptian patients and safety concerns particularly related to infections and some rare Diabetic Ketoacidosis (DKA). Also, usage of SGLT2 inhibitors is limited in the early stage of diabetes as they are usually preferred as 3rd or 4th add-on therapy. The existing dapagliflozin phase-3 clinical trial program on SGLT2 inhibitors didn't include subjects from Egypt. There is no study available which evaluates the effect of dapagliflozin in real world scenario in Egypt. Key opinion leaders in diabetes in Egypt have also identified the need for study on Egyptian subjects to observe the usage pattern and effect of dapagliflozin, a SGLT2 inhibitor, in this specific real world setting. Therefore, there is a need for data on real world setting across Egypt. With this aim in mind, the present study has been planned.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03624803
Study type	Observational
Source	AstraZeneca
Contact
Status	Completed
Phase
Start date	March 9, 2019
Completion date	March 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02797392` - Feasibility of a Preventive Program Against Lifestyle Related Diseases	N/A
Completed	`NCT01264523` - Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients	N/A
Completed	`NCT04105608` - GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients.	N/A
Terminated	`NCT01787214` - Walnuts and Glucose Variability	N/A
Completed	`NCT01715428` - Liraglutide and Cardio-Metabolic Risk Markers	N/A
Completed	`NCT01884714` - Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study	N/A
Completed	`NCT00567047` - Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment	Phase 1
Completed	`NCT02191644` - Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes	Phase 2
Completed	`NCT01440660` - Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)	N/A
Completed	`NCT01343589` - Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk	N/A
Completed	`NCT00651105` - Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects	Phase 3
Completed	`NCT04330911` - The Effects of Aerobic Exercises on Exercise Capacity in Type-2 Diabetes Mellitus	N/A
Completed	`NCT03269058` - Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes	Phase 4
Completed	`NCT04952948` - Pilates Method on Functional Capacity and Blood Pressure of Elderly Women With Type 2 Diabetes	N/A
Completed	`NCT00478127` - Hepatocyte Growth Factor and Cardiovascular Autonomic Function	N/A